My name is Christina Logan. I am 27 years old and have been diagnosed with Friedreich’s Ataxia for 7 years now. I am a strong advocate for the FA Community; I once was a FA Ambassador who managed the social media accounts for the Friedreich’s Ataxia Research Alliance (FARA), and I am now enrolled in my third clinical trial. I live independently and work full-time in Philadelphia, PA. I have an amazing support system of family, my fiancé- Justin, friends and FAmily who help me do what I do every day.
I truly believe in the quote, “hope is stronger than fear.” Hope is an emotion that my family and I feel after we attend the Friedrich’s Ataxia Symposium hosted by the Children’s Hospital of Philadelphia (CHOP) every year. The past symposium, held in October 2017, Takeda Pharmaceuticals was discussed during the research pipeline presented by FARA’s Executive Director, Jennifer Farmer. She mentioned that Takeda Pharmaceuticals had a phase 2 trial planned for TAK-831. The purpose of this study is to see if TAK-831 improves daily activities of life by evaluating upper limb motor function and manual dexterity. What stuck out to me the most is the possibility of improving daily activities of life and dexterity.Add a comment